Xiamen Amoytop Biotech boosts capital, expands children's health support

Xiamen Amoytop Biotech announced a capital increase following the vesting of the first tranche of its 2024 restricted stock incentive plan. The change, which adds 1,389,480 shares to its total share capital, was approved by the board of directors on November 17, 2025, and will result in corresponding amendments to the company's Articles of Association. The revised Articles, reflecting the new registered capital, have been disclosed on the Shanghai Stock Exchange website.

In a separate but related announcement, the company also disclosed a philanthropic initiative, approved by the board on November 17, 2025. Xiamen Amoytop Biotech will donate up to 40,000 units of "Yipei Growth Hormone Injection" and cash not exceeding RMB 661,600 to the Beijing Red Heart Tongxiang Public Welfare Foundation. This donation aims to support the "Yi Lu Xiang Ban" patient assistance program, which aids children with growth hormone deficiency.

These donations, sourced from the company's own funds, are part of Xiamen Amoytop Biotech's commitment to social responsibility and are not expected to materially impact current or future operating performance. The company’s total donations over the past twelve months, including this latest contribution, amount to RMB 81,155,400, supporting various public welfare and scientific research activities.